Cite
HARVARD Citation
Weiss, L. et al. (2016). Rosuvastatin Is Effective to Decrease CD8 T-Cell Activation Only in HIV-Infected Patients With High Residual T-Cell Activation Under Antiretroviral Therapy. Journal of acquired immune deficiency syndromes. p. . [Online].